Skip to content

Black Raspberry Nectar for the Prevention of Lung Cancer, BE WELL Study

The BE WELL Study: Black Raspberry Beverage Working to Prevent Lung Cancer

Status
Completed
Phases
Early Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04267874
Enrollment
96
Registered
2020-02-13
Start date
2019-10-25
Completion date
2021-06-13
Last updated
2023-12-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Carcinoma, Tobacco-Related Carcinoma

Brief summary

This trial studies how well black raspberry nectar works in changing the gut microbiome and in reducing inflammatory processes that may lead to lung cancer. Studying the effects of black raspberry beverage on inflammation may help doctors find strategies to reduce the risk of developing lung cancer.

Detailed description

PRIMARY FEASIBILITY OBJECTIVE: I. To evaluate the feasibility of establishing a diet intervention trial with longitudinal microbiome collection in Ohio State University Comprehensive Cancer Center (OSUCCC) Lung Cancer Screening Clinic (OSUCCC-LCSC). PRIMARY SCIENTIFIC OBJECTIVE: I. To determine the impact of the black raspberry (BRB) nectar intervention on the microbiome and inflammatory biomarkers. OUTLINE: Patients are randomized to 1 of 2 arms. ARM I: Patients receive BRB nectar orally (PO) twice daily (BID) for weeks 0-4 and then receive placebo PO BID for weeks 6-10 in the absence of unacceptable toxicity. Patients also undergo collection of nasal swabs, blood, urine, and stool samples at weeks 0, 4, 6, and 10. ARM II: Patients receive placebo PO BID for weeks 0-4 and then receive BRB nectar PO BID for weeks 6-10 in the absence of unacceptable toxicity. Patients also undergo collection of nasal swabs, blood, urine, and stool samples at weeks 0, 4, 6, and 10.

Interventions

PROCEDUREBiospecimen Collection

Undergo collection of nasal swabs, blood, urine, and stool

DIETARY_SUPPLEMENTNutritional Supplementation

Given black raspberry nectar PO

DRUGPlacebo Administration

Given PO

OTHERQuestionnaire Administration

Ancillary studies

Sponsors

Ohio State University Comprehensive Cancer Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
PREVENTION
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
55 Years to 77 Years
Healthy volunteers
Yes

Inclusion criteria

* Have a 30 pack-year smoking history * Be either a current smoker or a former smoker that quit in the last 15 years. Any individual who is currently smoking and has smoked more than 100 cigarettes in their lifetime will be identified as a current smoker * Agree to consume a standardized vitamin / mineral supplement and avoid other nutritional, dietary or alternative medications / supplements / probiotics for the duration of the study * Agree to follow a berry-free / controlled phenolic diet and to document consumption of polyphenolic foods each day of the study using a simple daily form

Exclusion criteria

* Person has an allergy to any berries, pectin, or food colorants apples,as well as kiwi fruit, strawberries, soy sauce, pine nuts, almonds, cherries, peaches, blackberries, pears * Person states that they are not a: * Current smoker: active cigarette smoker who has smoked more than 30 pack-years in the last 15 years OR * Former smoker: not a current smoker active cigarette smoker who has smoked more than 30 pack years in the last 15 years * Person is unwilling to follow a berry-free/controlled polyphenol diet while on study * Person has history of metabolic disorders (diabetes, hyper/hypo-thyroidism, etc.); digestive illness which may result in nutrient malabsorption (Crohn's disease, Celiac, renal/hepatic insufficiency, short bowel, etc.); disorders that affect connective tissues; or blood clotting disorders * Person has allergy or food intolerance to ingredients in study products (black raspberries or other berries) * Person is on a regimen of any of the following medications: * Immunosuppressants, bisphosphonates, or steroids. * Anticoagulants (warfarin, apixaban, dabigatran, and rivaroxaban) * Probiotics * Person is undergoing treatment for cancer in any form * Person is currently pregnant or nursing or plans to become pregnant during this study * Person plans to enter smoking cessation or change their smoking status during the course of the study

Design outcomes

Primary

MeasureTime frameDescription
Recruitment ratesUp to 3 yearsRecruitment rates will be defined as the proportion of screened accrued relative to those approached. Successful recruitment rates will be defined as \>= 10% of participants approached agree to participate.
Study adherenceUp to 3 yearsStudy adherence will be defined as the percent of the biospecimens collected at the end of the study period, with a compliance goal of 60%. Will track the monthly collection of data and document reasons for missing any scheduled collection dates. The proportions of missing information at each time point will be calculated. Descriptive statistics will examine the distribution of all patient and treatment characteristics, overall and by patient and disease characteristics.
Inflammatory markers found in nasal brushingsUp to 3 yearsEvaluated by ribonucleic acid sequencing.
Changes in stool microbe relative abundancesUp to 3 yearsEvaluated by metagenomic whole sequencing.
Biologic responses to the black raspberry (BRB) nectarUp to 3 yearsSamples of urine, stool. and blood will be analyzed for BRB phytochemicals (ellagitannins, ellagic acid, quercetin glycosides, anthocyanins) and their metabolites (urolithins, quercetin glucuronides/sulfates, methylated anthocyanins).

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 12, 2026